Latest News
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
2 October 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), which develops medicines across neuroscience and immunology, on Friday released new analyses supporting ecopipam for paediatric Tourette s...
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
2 October 2026 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and adolescents with moderate high-impact plaque psoriasi...
Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body
2 October 2026 - Clear Scientific, Inc., a US-based biopharmaceutical company, on Thursday announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that is claimed to immediately bind and inactivate fentanyl...
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
2 October 2026 - Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new publication in the Journal of the American Chemical ...
PearlMatrix P-15 Peptide Enhanced Bone Graft receives Medicare New Technology Add-on Payment (NTAP) status
2 October 2026 - Cerapedics Inc., a US-based, commercial-stage musculoskeletal company involved in bone repair, announced on Thursday that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status ...